Equity research analysts covering Organogenesis Holdings Inc. (ORGO) maintain a 12-month consensus average price target hovering around $4.33 to $5.00 per share, with individual professional projections spanning from conservative near-term estimates up to an upper bull-case target of $8.00. These target valuations are formulated based on projected revenue acceleration from advanced wound care products, scaling gross profit margins, and anticipated milestones in clinical pipeline development.